The global UNAIDS target is 3 million active PrEP users by the end of 2020 but as of June there were only an estimated 575,000 enrolled. Despite slow roll-out initially, there are now at least 78 countries offering PrEP but with less diversity in service models than seen in differentiated ART delivery. Pre-COVID-19, there was a move towards more community-based or virtual/Telehealth models that have since been accelerated during COVID-19 country lock-downs. In this session, we will highlight how some countries have rapidly pivoted PrEP programming be more differentiated and truly client-centered—offering online, community, and private-sector service options to expand and maintain access. In the live session, perspectives from providers, PrEP users, ministry of health, and global normative agencies will also be shared with a moderated discussion on how a differentiated approach to PrEP will be essential to significantly increase uptake by the end of 2020 and beyond!

The global UNAIDS target is 3 million active PrEP users by the end of 2020 but as of June there were only an estimated 575,000 enrolled. Despite slow roll-out initially, there are now at least 78 countries offering PrEP but with less diversity in service models than seen in differentiated ART delivery. Pre-COVID-19, there was a move towards more community-based or virtual/Telehealth models that have since been accelerated during COVID-19 country lock-downs. In this session, we will highlight how some countries have rapidly pivoted PrEP programming be more differentiated and truly client-centered—offering online, community, and private-sector service options to expand and maintain access. In the live session, perspectives from providers, PrEP users, ministry of health, and global normative agencies will also be shared with a moderated discussion on how a differentiated approach to PrEP will be essential to significantly increase uptake by the end of 2020 and beyond!

What's the 2+1+1? In July 2019, the World Health Organization updated its PrEP guidance to include the 4-pill (2+1+1) event-driven (ED)-PrEP dosing regimen for men who have sex with men (MSM). ED-PrEP is as equally efficacious as daily oral PrEP when taken correctly, and provides flexibility and choice to those who may not need a daily pill to protect themselves from HIV. ED-PrEP offers the additional advantage of clear guidance on when to start and stop PrEP, reduced cost to users, and lower drug exposure. This session will highlight first experiences in implementing ED-PrEP in early adopter lower- and middle-income countries, sharing key milestones, lessons learned, and challenges overcome. It will also feature a panel discussion on what can be done to further increase access to ED-PrEP among MSM from the perspectives of policy makers, scientists, advocates, and PrEP users themselves.

Tuberculosis is the leading cause of mortality among persons living with HIV (PLHIV), accounting for a third of AIDS-related deaths in 2019. While estimates suggest that PLHIV are 19 times more likely to contract TB, case-finding among PLHIV remains low with 49% unaware of their coinfection. WHO-recommended LF-LAM facilitates quicker TB diagnosis and initiation on treatment (or TB preventive therapy for those without active TB) among PLHIV, but uptake of this test in high TB/HIV burden countries has been too slow. In this session, we will explore barriers to TB diagnosis among PLHIV, spotlight successful adoptions of LF-LAM, highlight results from existing LF-LAM, and preview other diagnostic tools in the pipeline. The session will also include a panel discussion outlining what needs to be done to accelerate access to appropriate tests and treatments to reduce TB-related deaths among PLHIV.

The global UNAIDS target is 3 million active PrEP users by the end of 2020 but as of June there were only an estimated 575,000 enrolled. Despite slow roll-out initially, there are now at least 78 countries offering PrEP but with less diversity in service models than seen in differentiated ART delivery. Pre-COVID-19, there was a move towards more community-based or virtual/Telehealth models that have since been accelerated during COVID-19 country lock-downs. In this session, we will highlight how some countries have rapidly pivoted PrEP programming be more differentiated and truly client-centered—offering online, community, and private-sector service options to expand and maintain access. In the live session, perspectives from providers, PrEP users, ministry of health, and global normative agencies will also be shared with a moderated discussion on how a differentiated approach to PrEP will be essential to significantly increase uptake by the end of 2020 and beyond!

The global UNAIDS target is 3 million active PrEP users by the end of 2020 but as of June there were only an estimated 575,000 enrolled. Despite slow roll-out initially, there are now at least 78 countries offering PrEP but with less diversity in service models than seen in differentiated ART delivery. Pre-COVID-19, there was a move towards more community-based or virtual/Telehealth models that have since been accelerated during COVID-19 country lock-downs. In this session, we will highlight how some countries have rapidly pivoted PrEP programming be more differentiated and truly client-centered—offering online, community, and private-sector service options to expand and maintain access. In the live session, perspectives from providers, PrEP users, ministry of health, and global normative agencies will also be shared with a moderated discussion on how a differentiated approach to PrEP will be essential to significantly increase uptake by the end of 2020 and beyond!

The global UNAIDS target is 3 million active PrEP users by the end of 2020 but as of June there were only an estimated 575,000 enrolled. Despite slow roll-out initially, there are now at least 78 countries offering PrEP but with less diversity in service models than seen in differentiated ART delivery. Pre-COVID-19, there was a move towards more community-based or virtual/Telehealth models that have since been accelerated during COVID-19 country lock-downs. In this session, we will highlight how some countries have rapidly pivoted PrEP programming be more differentiated and truly client-centered—offering online, community, and private-sector service options to expand and maintain access. In the live session, perspectives from providers, PrEP users, ministry of health, and global normative agencies will also be shared with a moderated discussion on how a differentiated approach to PrEP will be essential to significantly increase uptake by the end of 2020 and beyond!

What's the 2+1+1? In July 2019, the World Health Organization updated its PrEP guidance to include the 4-pill (2+1+1) event-driven (ED)-PrEP dosing regimen for men who have sex with men (MSM). ED-PrEP is as equally efficacious as daily oral PrEP when taken correctly, and provides flexibility and choice to those who may not need a daily pill to protect themselves from HIV. ED-PrEP offers the additional advantage of clear guidance on when to start and stop PrEP, reduced cost to users, and lower drug exposure. This session will highlight first experiences in implementing ED-PrEP in early adopter lower- and middle-income countries, sharing key milestones, lessons learned, and challenges overcome. It will also feature a panel discussion on what can be done to further increase access to ED-PrEP among MSM from the perspectives of policy makers, scientists, advocates, and PrEP users themselves.

Tuberculosis is the leading cause of mortality among persons living with HIV (PLHIV), accounting for a third of AIDS-related deaths in 2019. While estimates suggest that PLHIV are 19 times more likely to contract TB, case-finding among PLHIV remains low with 49% unaware of their coinfection. WHO-recommended LF-LAM facilitates quicker TB diagnosis and initiation on treatment (or TB preventive therapy for those without active TB) among PLHIV, but uptake of this test in high TB/HIV burden countries has been too slow. In this session, we will explore barriers to TB diagnosis among PLHIV, spotlight successful adoptions of LF-LAM, highlight results from existing LF-LAM, and preview other diagnostic tools in the pipeline. The session will also include a panel discussion outlining what needs to be done to accelerate access to appropriate tests and treatments to reduce TB-related deaths among PLHIV.